Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell onAugust 31. Jacobio will collaborate with Hebecell to develop thenext-generation natural killer cell therapy based...

2021-08-31 22:05 3061

Jacobio Pharmaceuticals Announces 2021 Interim Results

BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced its results for the first half of 2021. Investment in R&D for the clinical-stage biotech firm reached175 million yuan (approx. US$27 million) for the half year, up 146 percent ye...

2021-08-31 22:01 4073

Viva Biotech Announced 2021 Interim Results

Revenue Increased by 419.5% YoY, CRO Business Income Increased by 62.5% YoY, O rderBacklog Recorded a Significant Increase of 72% Financial Highlights for the 6 months ended June 30, 2021: * Revenue amounted to RMB1,026.5 million, representing a year-on-year (YoY) increase of approximately 419...

2021-08-31 01:32 4806

Everest Medicines Announces Half-Year 2021 Interim Results

SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-08-30 22:15 3599

Everest Medicines Announces Up to HK$100 million Share Repurchase Program

2021-08-30 22:03 3056

Alphamab Oncology Reports 2021 Interim Results and Business Highlights

SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the company's interim results for the six months ended on June 30, 2021, and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "In 2021 ...

2021-08-30 10:51 3566

Innovent to Present New Data on Sintilimab and Other Molecules at the European Society for Medical Oncology (ESMO) Congress 2021

SAN FRANCISCO and SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...

2021-08-30 08:00 3189

Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer

SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that the former President and Head of Research & Clinical Development, Dr.Henri Nico Doods, will serve as the company's Chief Executive Officer. Dr...

2021-08-30 08:00 4150

Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer

Innovent and Bolt Biotherapeutics Announce Collaboration to Develop Three New Oncology Boltbody™ ISAC Programs

SAN FRANCISCO and SUZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-08-27 08:00 4449

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million

HANGZHOU, China, Aug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of$50 million, with Lilly Asia Ventures (LAV) as lead ...

2021-08-27 08:00 4064

JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions

Population–based cohort study from Canada is first to describe patterns of mortality, both cancer-related and otherwise, for people with different types of NETs. PLYMOUTH MEETING, Pa., Aug. 27, 2021 /PRNewswire/ -- Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer...

2021-08-27 03:30 1700

Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases

SHANGHAI, Aug. 27, 2021 /PRNewswire/ -- Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)-driven drug discovery company, and4B Technologies Co., Ltd. ("4B Technologies"), a leading end-to-end innovative biopharmaceutical company focusing on nervous system diseases, signed...

2021-08-27 03:22 28242

Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases

Modern Chinese Medicine Announces Year 2021 Interim Results

PERFORMANCE HIGHLIGHTS * Revenue increased by 8.8% to RMB171.8 million * Gross profit increased by 10.4% to RMB78.6 million * Profit after tax increased by 10.5% to approximately RMB44.1 million * The increase in revenue was primarily driven by the surge in revenue generated from the sales...

2021-08-26 20:46 4734

INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800

INOVIO's global Phase 3 efficacy trial receives authorization to proceed from Brazil; other countries to follow INOVIO to conduct INNOVATE Phase 3 efficacy trial with partner Advaccine in areas of world in need of COVID-19 vaccines PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- INOVIO (NAS...

2021-08-26 20:00 2567

RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its financial results and operational highlights for the second quarter...

2021-08-26 19:56 4921

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibiti...

2021-08-26 19:50 2708

CStone Pharmaceuticals Announces 2021 Interim Results

SUZHOU, China, Aug. 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precision medicines, today announced 2021 financial results. "In the first...

2021-08-26 19:14 4637

Innovent Announced 2021 Interim Results with Total Revenue of RMB 1,941.8 Million and Accelerated Global R&D Footprint

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-08-25 20:53 4421

Kintor Pharma Collaborates with Etana to Commercialize Proxalutamide for Treatment of COVID-19 in Indonesia

SUZHOU, China, Aug. 25, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that it has entered into a licensing agreement with PT Etana Biotechnol...

2021-08-25 19:25 3102

Moolec Science and Grupo Insud Launch Food-Tech Joint Venture

WARWICK, England, Aug. 25, 2021 /PRNewswire/ -- Moolec, a science-based ingredients company using plants to produce animal proteins, andGrupo Insud, a global conglomerate with a strong presence in the manufacturing of biosimilars and other active ingredients for the pharmaceutical industry, annou...

2021-08-25 18:00 1254

1 ... 106 107 108109110 111 112 ... 181